Meeting
2020 ASCO Virtual Scientific Program
Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
Authors
Lindsey Fitzgerald
Huntsman Cancer Institute-University of Utah Health Care, Salt Lake City, UT
Lindsey Fitzgerald , Adam Kittai , Loretta J. Nastoupil , Alexandra Waller , Caron A. Jacobson , Anna Saucier , Manali K. Kamdar , Janet Spradley , Nathan Denlinger , Jonathan Chipman , Boyu Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8039)
DOI
10.1200/JCO.2020.38.15_suppl.8039
Abstract #
8039
Poster Bd #
372
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Real-world versus clinical trial CAR T outcomes among patients diagnosed with diffuse large B-cell lymphoma.
First Author: Kaitlyn McBride
Poster
2021 ASCO Annual Meeting
Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).
First Author: Caron A. Jacobson
Poster
2018 ASCO Annual Meeting
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
First Author: Peihua Lu
Poster
2023 ASCO Annual Meeting
Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).
First Author: Matthew J. Frigault